30 results about "Virus-like particle" patented technology

Embodiments of the invention disclosed herein involve the selective engineering of Sindbis virus so as to generate cells that make enveloped virus-like particles that contain therapeutic mRNAs, and whose membrane proteins have been mutated to serve as modular binding sites for cell-targeting ligands.

The present disclosure provides virus-like particles (VLPs) comprising: i) a CRISPR-Cas effector polypeptide; ii) a recombinant lentivirus comprising a nucleotide sequence encoding a therapeutic polypeptide having a length of from about 250 amino acids to about 3,000 amino acids, where the VLP comprises a pseudotyping viral glycoprotein and / or a polypeptide that provides for binding to a target cell. The present disclosure provides systems for producing a VLP. The present disclosure provides methods of delivering a therapeutic protein, using a VLP of the present disclosure.

This invention belongs to the field of bioengineering and virus-like particle (VLP) construction technology, specifically relating to an amino acid sequence with steric hindrance effect and its preparation method, the VP2 protein of recombinant porcine parvovirus and its nucleotide sequence, and the virus-like particles assembled from it. An amino acid sequence with steric hindrance effect, SEQ ID NO: 1, is provided. This invention provides an amino acid sequence with steric hindrance effect, which is fused to the N-terminus of the wild-type VP2 protein to obtain a modified VP2 protein. During the critical phase of the assembly of the modified VP2 protein into VLPs, SEQ ID NO: 1 at the N-terminus, due to its steric hindrance effect, pre-occupies and physically seals the 5-fold pores of the capsid, ensuring that the host background nucleic acid cannot enter the particle interior. Through protein structure modification, nucleic acid entry into the particle interior is physically blocked from the source, resulting in a pure antigen with extremely high hollowing rate.

The present invention relates to a platform concept for presenting antigenic polypeptides as part of a virus like particle (VLP) construct, which comprises a Gag (group-specific antigen) protein of a beta-retrovirus, for instance of a human endogenous retrovirus K (HERV-K) or of IAPE. Surprisingly it was found that antigenic polypeptide expression in a VLP comprising a Gag protein of HERV-K or of murine endogenous retrovirus IAPE (Intracisternal A-type Particles elements with an Envelope) promotes antigenic polypeptide display and immunogenicity.

This invention relates to genetic engineering technology and aims to provide a method for preparing and applying bacteriophage capsid protein MS2-armored PRRSV antigen mRNA particles. The method includes: inserting the MS2 bacteriophage capsid protein gene and an mRNA expression cassette into a double multiple cloning site expression vector; transforming the recombinant expression plasmid into host bacteria; inducing expression to allow the MS2 capsid protein to express and self-assemble into virus-like particles; utilizing the specific recognition of the MS2 capsid protein on the packaging stem-loop structure, packaging the transcribed mRNA inside the virus-like particles to form MS2-armored PRRSV antigen mRNA particles; lysing the host bacteria, separating the supernatant, and enriching and purifying the particles. This invention significantly enhances the resistance of mRNA to nuclease degradation and improves formulation stability; it can increase the efficiency of mRNA entering antigen-presenting cells and enhance immunogenicity; it can be mass-produced with controllable processes and relatively low cost.

The application discloses a CMV virus-like particle for producing a VLP recombinant vaccine and a preparation method thereof, the CMV virus-like particle is obtained by cloning a C-terminal G4SLPETG modified plant virus cucumber mosaic virus CMV capsid gene into a prokaryotic expression vector to obtain a recombinant expression vector, the recombinant expression vector is transfected into E. coli BL21 (DE3), and expression is obtained through the recombinant E. coli BL21 (DE3); and the amino acid sequence of the C-terminal G4SLPETG modified CMV is SEQ ID NO. 1. Test proves that the recombinant strain constructed by the application is stable to expression of an exogenous protein. The recombinant protein expressed by the application is used for preparing a virus-like particle for antigen coupling, the coupling efficiency is high, the antigen purity is high, the safety is good, the virus-like particle is not pathogenic to mice and other animals, and the safety evaluation is easy.

The application discloses a method for constructing a cell membrane fusion model induced by a novel coronavirus-like particle, and belongs to the technical field of biology. The method comprises the following steps: constructing a virus-like particle containing a SARS-CoV-2 spike protein gene and an RNA packaging sequence PS9, using HEK-293T cells as packaging cells, co-expressing structural proteins M, E, N and S protein, and realizing assembly of VLPs without replication ability. Subsequently, the VLPs are used to infect immortalized type II alveolar epithelial cells, S protein expression is induced and cell-cell membrane fusion is mediated without the need of BSL-3 laboratory conditions. The formation of fused giant cells can be directly observed through ZO-1 protein immunofluorescence staining, the model is stable, has high biological safety, and is repeatable in vitro. The application overcomes the safety risk of live virus infection and the authenticity problem of a transient transfection model, can be used for research on a SARS-CoV-2 virus membrane fusion mechanism, and has a good application prospect.

This disclosure especially The use of RNA molecules (e.g., RNA hairpin agonists) that bind to and activate RIG-I-like receptors (RLRs), including RLR agonists packaged in virus-like particles (VLPs), in methods for treating a condition (e.g., cancer) or improving one or more symptoms of said condition.

Disclosed herein are synthetic VP1 proteins that contain engineered disulfide bonds. In some embodiments, the synthetic VP1 proteins with engineered disulfide bonds self-assemble into non-infectious virus-like particles (VLPs) that are more stable that non-infectious VLPs that resulted from self-assembly of VP1 proteins that lack engineered disulfide bonds.

The application discloses a kind of MS2 virus-like particles based on capsid protein site-directed mutation and its preparation method and application, belong to molecular biological technique field.The amino acid of the beta sheet interface of capsid protein sequence, the amino acid of the interface when two capsid proteins molecules assemble, the carboxyl end site of capsid protein is subjected to site-directed mutation, obtain the mutant that can significantly improve the assembly efficiency and stability of capsid protein dimer.Utilize the mutant to construct MS2 virus-like particles, further by the design of mature enzyme and capsid protein expression element, control mature enzyme weak expression, capsid protein strong expression, to improve assembly efficiency.The application improves the assembly efficiency of MS2 virus by the above strategy, improves the proportion of wrapped RNA, enhances the stability of virus-like particle, greatly prolongs the stable storage time of RNA, improves the purity of wrapped RNA.

The present disclosure relates to a recombinant protein comprising a food and mouth disease virus (FMDV) virus like particle (VLP) and a fragment crystallizable region (Fc) of a swine-derived immunoglobulin linked to the surface of the VLP, and a vaccine composition comprising the recombinant protein. The recombinant protein of the present disclosure may form a self-assembling structure including a virus-like particle using a protein derived from a capsid protein of FMDV, which is an antigenic protein, and a swine Fc protein located on the surface of the virus-like particle, and by using a vaccine composition including the recombinant protein, a specific antibody against FMDV may be effectively produced.

The present disclosure provides a virus like particle comprising a viral structural protein and a galectin epitope peptide, and a composition or vaccine comprising thereof, its use in a medicine, particularly in an immunotherapy.

The present invention provides highly efficient methods, and compositions related thereto, for generating high titer human antibodies or antibody fragments thereof in a mammalian subject. The methods comprise administering a virus or virus-like particle to a mammal comprising heterologous immune cells and isolating a population of immunoglobulin-producing cells from the mammal, thereby producing the antibodies or antibody fragments thereof.

An immunomodulatory nanoparticle vaccine carrier protein and its application. This invention uses duck hepatitis B virus core antigen (DHBc) as a base, fuses and expresses the SpyCatcher003 sequence to construct DHBc-SpyCatcher (DHBc-SC) virus-like particles with self-assembly capability, and efficiently expresses them in *E. coli*. When DHBc-SC virus-like particles are mixed with heterologous monomeric antigens containing SpyTag, they can spontaneously couple to form virus-like particles displaying the heterologous antigen, significantly enhancing the immunogenicity of the heterologous antigen.

There is provided an immunogenic composition comprising or consisting of a recombinant Cyanobacteria or lysate thereof wherein the recombinant Cyanobacteria comprises a nucleic acid encoding at least one VLP and at least one heterologous antigen, wherein the expressed VLP comprises the at least one heterologous antigen.

Disclosed herein is an oral fish vaccine comprising a recombinant cell comprising virus-like particles, wherein the recombinant cell is intact, inactivated, and does not exhibit antibiotic resistance. In one preferred embodiment, the inactivation is performed using sodium hypochlorite. In another preferred embodiment, the recombinant cell is Escherichia coli (E. coli) or Lactococcus lactis (L lactis). In a further preferred embodiment, the virus-like particles comprise nervous necrosis virus capsid proteins and the vaccine is used in treating or preventing viral nervous necrosis.

The present invention relates to immunogen carriers, wherein said immunogen carriers are preferably virus-like particles (VLPs) comprising a plurality of modified PCV2 ORF2 proteins. In particular, the present invention belongs to the field of compliance markers and marker vaccines allowing to distinguish between infected and vaccinated individuals. In particular, it relates to compliance markers for vaccines comprising subunit antigens and DIVA (distinguishing infected from vaccinated animals) systems, which enable to distinguish between animals infected with a pathogen and animals treated with subunit antigens derived from said pathogen.

The present disclosure provides, among other things, a pharmaceutical composition that includes a lipid nanoparticle adjuvant and an anti-human papillomavirus (HPV) comprising HPV virus-like particles (VLPs) of at least one type of human papillomavirus (HPV) selected from the group consisting of HPV types: 6, 11, 16, 18, 26, 31, 33, 35, 39, 45, 51, 52, 53, 55, 56, 58, 59, 66, 68, 73, and 82.

The present invention relates to a modified virus-like particle (VLP) of Cucumber Mosaic Virus (CMV) comprising at least one fusion protein, wherein the at least one fusion protein comprises or preferably consists of b) a chimeric CMV polypeptide, wherein the chimeric CMV polypeptide comprises or preferably consists of (iii) a CMV polypeptide, wherein the CMV polypeptide comprises a coat protein of CMV; and (iv) an antigen polypeptide, wherein the antigen polypeptide is inserted into the CMV polypeptide, wherein the insertion of the antigen polypeptide is between amino acid residues corresponding to position 84 and position 85 of SEQ ID NO: 62 of the CMV polypeptide; and (iii) a T helper cell epitope, wherein the T helper cell epitope replaces an N-terminal region of the CMV polypeptide, and wherein preferably the N-terminal region of the CMV polypeptide corresponds to amino acids 2-12 of SEQ ID NO: 62.

This disclosure relates to engineered flavivirus envelope (E) peptides containing stem-transmembrane domain mutations, virus-like particles (VLPs) containing said engineered E peptides, and the use of said E peptides in the treatment and prevention of flavivirus infection.

Virus-Like Particles derived from the subfamilies, Parahepevirinae and Orthohepevirinae, particularly those of the species Paslahepevirus balayani, which can cause acute hepatitis in humans and several mammalian species, and chronic conditions in immunocompromised patients are disclosed. Compositions of VirusLike Particles comprising viral capsid proteins capable of assembly in cultured cells that may be purified, disassembled, and reassembled in the presence of other molecules suitable for use as therapeutic drug products to facilitate the targeting and delivery of cargo molecules to specific cells or tissues, or as antigenic agents designed to stimulate responses to heterologous epitopes exposed on the surfaces of Virus- Like Particles are provided. Functional capsids comprising polypeptide sequences comprising amino acid substitutions, insertions, or deletions of amino acid encoded by a consensus of ORF2 genes, that are functionally-similar or have enhanced properties compared to capsid polypeptides encoded by naturally-occurring viruses obtained from clinical samples or prototype Hepatitis E Viruses (HEV) are provided.

The present invention relates to a method for producing a bacterial microcompartment virus-like particle (VLP) carrying a cargo molecule, the method comprising introducing and expressing in a host cell or organism one or more polynucleotides comprising (a) a first sequence encoding bacterial microcompartment shell protomers and a second sequence encoding a cargo molecule fused to an encapsulation peptide comprising the sequence SKITGSSGNDTQGSLITYSGGARG, and forming a microcompartment that encapsulates the cargo molecule, or (b) a first sequence encoding bacterial microcompartment shell protomers and a second sequence encoding at least one of said protomers fused with a cargo molecule or a biochemical tag, and forming a microcompartment that expresses the cargo molecule or biochemical tag on an exterior surface. In one embodiment, the bacterial microcompartment protomers are CsoSIA and CsoS4A from Halothiobacillus neapolitanus, or HO-H, HO-P and HO-T1 from Haliangium ochraceum.

Disclosed are engineered virus-like-particles (VLPs) and their use. In the VPLs integral plasma membrane proteins are captured and displayed on the surface of a VLP in a native conformation based on an interaction between a viral scaffolding protein fused to a PDZ domain and a synthetic polypeptide in the cytoplasmatic C-terminal tail of the target membrane protein.

The application discloses an O-type foot-and-mouth disease virus multi-epitope virus-like particle nano-antigen and a preparation method and application thereof. The nano-antigen is obtained by sequentially connecting antigen epitopes of three topological representative strains O / Tibet / CHA / 99, O / Mya98 / BY / 2010, OZK / 93, O / XJPS / CHA / 2017 and O / HKN / 2007 of the O-type foot-and-mouth disease virus in sequence, introducing a T cell epitope of a 3A gene of the foot-and-mouth disease virus at a C terminal, and finally inserting a woodchuck hepatitis B virus core antigen, and an amino acid sequence of the nano-antigen is shown as SEQ ID NO. 6. Immunological test results show that the nano-antigen has good antigenicity, a vaccine prepared from the nano-antigen can not only induce high-level protective antibodies, but also protect immunized animals against virus attack. In addition, the nano-antigen has immunoprotective effects on the O-type foot-and-mouth diseases of pigs, cattle and sheep. The application provides an effective technical means for preventing and controlling and purifying the foot-and-mouth disease.

The present disclosure relates to, inter alia, RNA molecules (e.g., RNA hairpin agonists) that bind to and agonize RIG-I-like receptors (RLRs), and to use of the molecules, including RLR agonists packaged in virus like particles (VLPs), in methods for treating, or ameliorating one or more symptoms of, a disorder (e.g., cancer).

The present invention relates to a platform concept for presenting antigenic polypeptides as part of a virus like particle (VLP) construct, which comprises a Gag (group-specific antigen) protein of a beta-retrovirus, for instance of a human endogenous retrovirus K (HERV-K) or of IAPE. Surprisingly it was found that antigenic polypeptide expression in a VLP comprising a Gag protein of HERV-K or of murine endogenous retrovirus IAPE (Intracisternal A-type Particles elements with an Envelope) promotes antigenic polypeptide display and immunogenicity.

The present invention provides a medium composition containing a pyruvate dehydrogenase kinase inhibitor for promoting production of a virus carrying a gene of interest, when culturing virus-producing cells into which the gene of interest has been introduced, a medium composition for promoting production of virus or virus-like particles when culturing cells that produce the virus or virus-like particles, and the like.

The present invention provides an in-vitro method for transferring one or more nucleic acids sequences comprising one or more transgenes into γδ T cells with a pseudotyped retroviral vector particle or a virus-like particle thereof, wherein said pseudotyped retroviral vector particle or virus-like particle thereof comprises a modified baboon endogenous retrovirus (BaEV) envelope glycoprotein, the method comprising the steps a) activation of γδ T cells, b) contacting said pseudotyped retroviral vector particle or virus-like particle thereof with said activated γδ T cells using a low concentration of said pseudotyped retroviral vector particle, c) expanding said genetically modified γδ T cells in the absence of an aminobisphosphonate and in the presence of IL-2 and IL-15, wherein said expansion is in the absence of feeder cells and in the absence of human serum, and wherein at least 75% of the transduced and expanded γδ T cells are CD45RA-γδ T cells.